INOZYME PHARMA, INC. Deferred Tax Assets, Net of Valuation Allowance
INOZYME PHARMA, INC. had Deferred Tax Assets, Net of Valuation Allowance of $154.00 thousand as of 2024-12-31, per its 10-K filed 2025-03-10.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsNet · last filed 2025-03-10
- 2024-12-31: Deferred Tax Assets, Net of Valuation Allowance $154.00K.
- 2023-12-31: Deferred Tax Assets, Net of Valuation Allowance $410.00K.
- 2022-12-31: Deferred Tax Assets, Net of Valuation Allowance $609.00K.
- 2021-12-31: Deferred Tax Assets, Net of Valuation Allowance $810.00K.
| Period end | Deferred Tax Assets, Net of Valuation Allowance |
|---|---|
| 2024-12-31 | $154.00K 10-K · filed 2025-03-10 |
| 2023-12-31 | $410.00K 10-K · filed 2025-03-10 |
| 2022-12-31 | $609.00K 10-K · filed 2024-03-12 |
| 2021-12-31 | $810.00K 10-K · filed 2023-03-22 |
| 2020-12-31 | $372.00K 10-K · filed 2022-03-15 |
| 2019-12-31 | $12.00K 10-K · filed 2021-03-25 |